ST-246 (tecovirimat monohydrate) suspension formulations
AssigneeSiga Technologies, Inc.
InventorsShanthakumar R. Tyavanagimatt, Kris Holt, Ying Tan, Melialani A. C. L. S. Anderson, Dennis E. Hruby
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a dry suspension for reconstitution containing Tecovirimat (ST-246) powder and simethicone. The dry suspension is dispersed in water to provide an aqueous pharmaceutical suspension formulation for oral administration for treating orthopoxvirus infections and/or eczema vaccinatum. The suspension formulation exhibits excellent stability and good dissolution and has an improved taste and texture.
Claims19
A dry suspension comprising polymorph Form I of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2-(1H)-yl)-benzamide (Tecovirimat (ST-246)) and simethicone.
Dependencies are inferred from the claim text.